SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 5 analyzed stories

Merck & Co., Inc. (MRK) Reports 56%–63% MASH Resolution at 52 Weeks

Merck said its Phase 2b trial of efinopegdutide met its main goal: MASH resolution without worsening fibrosis at 52 weeks occurred in 56%, 63% and 61% of participants across doses, compared with 13% on placebo. Fibrosis improvement ranged from 34% to 52%, versus 21% on placebo.

Published:

Updated:

What happened

Merck reported that its mid-stage study of efinopegdutide, an experimental weekly treatment for a chronic liver disease, met its main goal. After 52 weeks, 56% to 63% of treated participants had disease resolution without worsening liver scarring, compared with 13% given placebo.

Global impact / market context

The results are encouraging for the treatment’s development, but they do not show whether it will become available or how it may affect Merck’s business. Investors should note that this was a mid-stage study, not proof of a widely available treatment.

What to watch

  1. Check for further study results, which could add evidence about the treatment’s effects.
  2. Check whether Merck reports plans for later-stage studies, which would show how development may proceed.
  3. Check for updates on the study’s comparison with placebo and the reported liver-scarring results, which help put the findings in context.

Affected assets

  • Efinopegdutide
  • Merck & Co., Inc.

Evidence